Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-17T20:07:29.406Z Has data issue: false hasContentIssue false

Nutritional determinants of cognitive aging and dementia

Published online by Cambridge University Press:  09 November 2011

Martha C. Morris*
Affiliation:
Rush University Medical Center, 1725 W Harrison, Suite 206, Chicago, IL 60612, USA
*
Corresponding author: Professor Martha Clare Morris, fax +1 708 660 2104, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

The objective of this review is to provide an overview of nutritional factors involved in cognitive aging and dementia with a focus on nutrients that are also important in neurocognitive development. Several dietary components were targeted, including antioxidant nutrients, dietary fats and B-vitamins. A critical review of the literature on each nutrient group is presented, beginning with laboratory and animal studies of the underlying biological mechanisms, followed by prospective epidemiological studies and randomised clinical trials. The evidence to date is fairly strong for protective associations of vitamin E from food sources, the n-3 fatty acid, DHA, found in fish, a high ratio of polyunsaturated to saturated fats, and vitamin B12 and folate. Attention to the level of nutrient intake is crucial for interpreting the literature and the inconsistencies across studies. Most of the epidemiological studies that observe associations have sufficient numbers of individuals who have both low and adequate nutrient status. Few of the randomised clinical trials are designed to target participants who have low baseline status before randomising to vitamin supplement treatments, and this may have resulted in negative findings. Post-hoc analyses by some of the trials reveal vitamin effects in individuals with low baseline intakes. The field of diet and dementia is a relatively young area of study. Much further work needs to be done to understand dietary determinants of cognitive aging and diseases. Further, these studies must be particularly focused on the levels of nutrient intake or status that confer optimum or suboptimal brain functioning.

Type
70th Anniversary Conference on ‘Vitamins in early development and healthy aging: impact on infectious and chronic disease’
Copyright
Copyright © The Author 2011

Abbreviations:
AD

Alzheimer's disease

THF

tetrahydrofolate

After more than a decade of research on nutrition and the aging brain, a number of promising nutritional factors have emerged that are also important to neurocognitive development. This review describes the evidence for these nutritional factors that show the most promise in the prevention of neurodegenerative disease. Among these are antioxidant nutrients, B-vitamins, dietary fat composition and n-3 fatty acids. Each of these factors has a body of literature to support underlying biological mechanisms for association as well as evidence of association from prospective epidemiological studies. The clinical trial evidence for vitamin supplements has been disappointing, but very few of these trials were designed to test whether supplementation is effective in persons who have low nutrient status for that particular dietary component. In general, potential recommendations to maintain a healthy brain reflect those that have been demonstrated to maintain a healthy heart: physical activity combined with a diet that has a high ratio of unsaturated to saturated fats, vegetables, fruits and fish. In this review, we first describe common neurodegenerative diseases of aging and some basic fundamentals in nutrient absorption and physiological function. These sections are followed by a review of the evidence for each dietary component.

Dementia

Dementia is a condition that is non-specific to any one disease and is characterised by a loss of major brain function in two or more areas of cognition, such as memory, thinking, language, judgment and behaviour( Reference Brewer, Gabrieli, Preston and Goestz 1 ). Alzheimer's disease (AD) is the primary cause of dementia in persons aged 60 years and older, representing 60–80% of cases( Reference Evans, Funkenstein and Albert 2 ). The second most common cause is vascular dementia or dementia due to the occurrence of multiple strokes( Reference Bennett 3 ). Most degenerative dementia is caused by mixed pathologies characteristic of AD, cerebral infarctions and Lewy bodies( Reference Schneider, Arvanitakis and Bang 4 ). Although most dementias are irreversible, the course of some forms can be stopped or reversed if found soon enough (e.g. dementia due to vitamin deficiencies, brain tumours, chronic alcohol abuse and medication use)( Reference Brewer, Gabrieli, Preston and Goestz 1 ).

Alzheimer's disease

AD is a common condition in older age. The overall prevalence among individuals aged 65 years and older has been estimated to be 10–13%( Reference Evans, Funkenstein and Albert 2 , Reference Hebert, Scherr and Bienias 5 ) and the rate increases exponentially with older age: from 3% among 65–74-year-olds to 19% among 75–84-year-olds and nearly half (47%) of those aged 85 years and older( Reference Evans, Funkenstein and Albert 2 ). Because the oldest age groups are also the fastest growing in the USA, the number of individuals with AD is expected to almost triple from six million in 2010 to sixteen million by the year 2050( Reference Hebert, Beckett and Scherr 6 ). Thus, by mid-century approximately 25% of the USA population will be aged 65 years and older, and more than one-third will likely develop dementia( Reference Hebert, Beckett and Scherr 6 ).

The clinical diagnosis of AD requires impairment in memory and at least one other cognitive domain( Reference McKhann, Drachman and Folstein 7 ). The disease is neuropathologically characterised by extracellular deposition of amyloid β into senile plaques, intra-neuronal formation of neurofibrillary tangles composed of hyperphosphorylated τ protein, and loss of neurons and synapses in the neocortex, hippocampus and other subcortical areas of the brain( 8 ). The primary risk factors for late-onset AD include older age, the apoE-ε4 genotype, head injury, family history, low education and low participation in cognitively stimulating activities( Reference Reitz, Brayne and Mayeux 9 ). CVD conditions and risk factors are the primary focus of the current research in AD( Reference Reitz, Brayne and Mayeux 9 , Reference Davidglus, Bell and Berrettini 10 ). Among these factors are physical activity( Reference Larson, Wang and Bowen 11 ), diet( Reference Luchsinger, Noble and Scarmeas 12 ), hypertension( Reference Skoog, Lernfelt and Landahl 13 , Reference Kivipelto, Helkala and Laakso 14 ), obesity( Reference Whitmer, Gunderson and Barrett-Connor 15 ), hypercholesterolaemia( Reference Kivipelto, Helkala and Laakso 14 ), diabetes( Reference Luchsinger, Tang and Stern 16 ), heart disease( Reference Reitz, Brickman and Luchsinger 17 ), stroke( Reference Schneider, Wilson and Bienias 18 ), metabolic syndrome( Reference Kalmijn, Foley and White 19 , Reference Yaffe, Weston and Blackwell 20 ) and statin( Reference Solomon, Kareholt and Ngandu 21 , Reference Beydoun, Beason-Held and Kitner-Triolo 22 ) and non-steroidal anti-inflammatory( Reference t'Veld, Ruitenberg and Hofman 23 ) medications. The strong ties between CVD and diet and between CVD and dementia support the idea that diet also plays a role in dementia at the very least through its effect on cardiovascular-related conditions. Genetic causes of AD are restricted to early-onset cases in persons less than 60 years of age and account for only 1% of all cases( Reference Bekris, Yu and Bird 24 ).

Cognitive decline

Central to all degenerative dementias is decline in cognitive abilities. Thus, an important and complementary area of study is individual change over time in neuropsychological test performance. These types of studies do not require clinical neurological evaluation by expert neurologists and thus are less costly than are studies of dementia diagnosis. Also, larger populations can be studied to examine risk factor associations with cognitive decline earlier in the disease process resulting in greater statistical power and less bias than studies using clinical diagnosis of dementia( Reference Morris, Evans and Hebert 25 ). In this type of study design in which exposures of interest are related to within-person rates of cognitive decline, to the extent that potential confounding factors for individuals remain constant over the cognitive assessment periods, confounding bias is minimised( Reference Morris, Evans and Hebert 25 ). The outcome (change in neuropsychological test performance) is not subjected to biases in clinician diagnosis arising from cultural, educational or other reasons. The greater the number of cognitive tests administered at each assessment period and the greater the number of cognitive assessments, the more accurate the measure of cognitive decline.

Cognitive decline is not disease specific. Therefore, a finding of association between a risk factor and cognitive decline does not necessarily mean that one should observe an association between the risk factor and any one of the dementia diseases in that population. However, one might be concerned to observe a risk factor association with a specific type of dementia in the study population but not with cognitive decline. This could be an indicator of a spurious disease association or perhaps early disease effects on the risk factor.

Nutrition and the blood–brain barrier

Nutrients, by definition, are molecules that are essential for human function. Most are not synthesised in vivo and thus must be consumed through diet. Some dietary components, like cholesterol, are synthesised by human subjects and therefore considered non-essential. The brain is an organ with high metabolic activity and also a high rate of nutrient turnover. Nourishment of the brain occurs through a myriad of nutrient-specific transport systems and physiological mechanisms that serve to replace the constant turnover of nutrients. To enter the brain, nutrients are transported either from blood through cerebral capillaries of the blood–brain barrier or through the choroid plexus of the blood–cerebral spinal fluid barrier by mechanisms of facilitated diffusion, active transport, binding receptors and endosomes, and ion channels, among others( Reference Spector 26 ). Some of these nutrient transport systems, such as for glucose, ascorbic acid and folate, have homoeostatic functions that serve to transport less into the brain when plasma levels are high and more into the brain when plasma levels are low( Reference Spector 27 , Reference Pardridge 28 ).

Studies of nutrient deficiencies in animals and in human subjects help to understand the nutrients' roles in the brain. For example, vitamin E deficiency syndrome causes a number of neurological symptoms including ataxia, decreased vibration sensation, lack of reflexes, paralyses of eye muscles and decline in cognitive function( Reference Muller 29 Reference Koscik, Farrell and Kosorok 31 ).

Nutrient level and physiological function

A well-established principle of nutrition is that nutrient level has a non-linear, inverted U-shaped association with physiological function. Optimal function occurs over a fairly wide range of nutrient intake levels. However, both deficient levels and toxically high levels may result in marginal physiological function or even death. This basic nutritional principle plays an important role in interpreting results and inconsistencies among epidemiological studies and randomised clinical trials( Reference Morris and Tangney 32 , Reference Blumberg, Heaney and Huncharek 33 ). Study populations and clinical trial cohorts for which the range of nutrient level does not span levels associated with both marginal and optimal physiological function will not produce findings of association between the nutrient and the disease outcome.

Antioxidant nutrients

Underlying biologic mechanisms of antioxidant nutrients

The brain is a site of high metabolic activity and is especially prone to oxidative stress and damage to neural tissue( Reference Mecocci, MacGarvey and Kaufman 34 Reference Haigis and Yankner 36 ). A prevailing theory is that oxidative damage and neural inflammation are the underlying biological mechanisms of neurodegenerative disorders like AD and Parkinson's disease( Reference Christen 37 Reference Beal 40 ). There are two types of antioxidants in the body: antioxidant enzymes that prevent the generation of toxic substances and antioxidant nutrients that neutralise free radicals and singlet molecules of O( Reference Sardesai 41 ). The antioxidant enzymes require the availability of selected nutrients, including Mn, Cu, Se and Zn( Reference Sardesai 41 ). Antioxidant nutrients include vitamin E (tocopherols), vitamin C, carotenoids and flavonoids. The antioxidant nutrients may play more important roles in the aging brain than in other organs of the body due to the fact that there are relatively fewer antioxidant enzymes for neuronal protection( Reference Olanow 42 ). There is also evidence that vitamin E may play a role in the developing brain. For example, infants with cystic fibrosis who had prolonged deficiency levels of α-tocopherol (<300 μ/dl plasma) had statistically significantly lower scores (P<0·05) on cognitive tests in childhood( Reference Koscik, Farrell and Kosorok 31 , Reference Koscik, Lai and Laxova 43 ).

Epidemiological evidence from prospective studies for vitamin E in food

The prospective epidemiological studies of dietary vitamin E (i.e. from food sources) consistently show statistically significant inverse associations with incident dementia and AD, and with cognitive decline (Table 1). The one negative study was the Washington Heights-Inwood Columbia Ageing Project( Reference Luchsinger, Tang and Shea 44 ). One possible explanation for the negative finding may be that the Washington Heights-Inwood Columbia Ageing Project study population had a narrow range of low intake levels (4–7 mg/d for the quartile medians). The top quartile median intake level of 7 mg/d was in the lowest tertile of intake of 10 mg/d in the Rotterdam study that reported positive findings for vitamin E( Reference Engelhart, Geerlings and Ruitenberg 45 ).

Table 1. Prospective studies of dietary antioxidant nutrients and dementia outcomesFootnote *

AD, Alzheimer's disease; BLSA, Baltimore Longitudinal Study of Aging; Dem, dementia; Cog, cognitive; CHAP, Chicago Health and Ageing Project; EVA, Etude du Vieillissement Arteriél; MCI, mild cognitive impairment; MMSE, mini-mental status examination; 3MS, three mini-mental staus examinations; NHS, Nurses' Health Study; PAQUID, Persones Agèe QUID; WHICAP, Washington Heights-Inwood Columbia Ageing Project.

* Upward arrows indicate statistically significant increased risk; downward arrows, statistically significant decreased risk; –, no association; blank, not examined.

Marginally statistically significant (P=0·07) in low powered study.

Statistically significant interaction; inverse association in current smokers. No association overall.

Findings from studies of biochemical levels of vitamin E are less consistent than that for the self-reported diet studies (Table 1). A comparison of the ranges of biochemical vitamin E levels revealed that differences in the ranges could account for null findings in some studies. For example, population levels in the negative study by Ravaglia et al. ( Reference Ravaglia, Forti and Lucicesare 46 ) are likely too low to provide protective benefit; the highest tertile level of α-tocopherol of 6·5 μmol/mmol cholesterol was in the lowest tertile of that reported by Mangialasche et al., a positive study( Reference Mangialasche, Kivipelto and Mecocci 47 ). Similarly, the entire biochemical range of vitamin E levels in the Nurses’ Health Study( Reference Kang and Grodstein 48 ), a null study, may be within the optimum range for cognitive function; the lowest tertile of α-tocopherol (median 24·85 μmol/l) fell within the highest tertile of the Persones Agèe QUID study (<25 μmol/l)( Reference Helmer, Peuchant and Letenneur 49 ). In the Persones Agèe QUID study, which had a wide range of α-tocopherol levels, the risk of dementia was three times higher (P=0·03) in the lowest tertile (11–21 μmol/l) compared with the highest tertile (25–55 μmol/l) level( Reference Helmer, Peuchant and Letenneur 49 ). Another explanation for the seemingly inconsistent findings may be that total tocopherol intake is more important for neuroprotection than the individual tocopherols alone. In the Kungsholmen study( Reference Mangialasche, Kivipelto and Mecocci 47 ) plasma levels of total tocopherols, total tocotrienols and total vitamin E were each inversely associated with incident AD, but none of the individual tocopherols in isolation was associated. In fact, none of the biochemical studies found association with the individual tocopherols (Table 1).

Evidence for other antioxidant nutrients

At this stage in the research there is weak evidence to support protection against dementia by dietary intake of other antioxidant nutrients (e.g. vitamin C, β-carotene and flavonoids). Only the Cache County Study( Reference Zandi, Anthony and Khachaturian 50 ) found protective benefit with high dietary intakes of vitamin C and β-carotene against the development of dementia (Table 1). Investigators from the Rotterdam study initially reported statistically significant inverse associations after 6 years of follow-up for vitamin C, and for smokers only, for β-carotene and flavonoids( Reference Engelhart, Geerlings and Ruitenberg 45 ). However, these protective associations were not maintained after 9·6 years of follow-up; only the inverse association for vitamin E remained statistically significant( Reference Devore, Grodstein and van Rooij 51 ) (Table 1).

Absence of evidence for antioxidant vitamin supplements

A number of prospective epidemiological studies( Reference Luchsinger, Tang and Shea 44 , Reference Zandi, Anthony and Khachaturian 50 , Reference Fillenbaum, Kuchibhatla and Hanlon 52 Reference Maxwell, Hicks and Hogan 57 ) and four randomised clinical trials( Reference Kang, Cook and Manson 58 Reference Petersen, Thomas and Grundman 61 ) examined the relation of vitamin E supplement use to AD or cognitive decline. With few exceptions( Reference Zandi, Anthony and Khachaturian 50 ) both types of studies found null associations of vitamin E supplement use with the cognitive outcomes. Dose level may play a role in the negative findings of studies that investigated α-tocopherol supplements. Vitamin supplement users and clinical trial participants tend to be healthy behaviour-seeking individuals and their diets likely already provide sufficient levels of nutrients for optimum functioning. In the Chicago Health and Ageing Project, vitamin E supplement use was inversely associated with cognitive decline but only among the participants who had low levels of intake from food( Reference Morris, Evans and Bienias 55 ). In this study, vitamin E supplementation was not associated with further reductions in the rate of cognitive decline among participants who had high food-intake levels of vitamin E. Post-hoc analyses of the Women's Health Study randomised trial revealed a statistically significant effect of vitamin E supplementation on the rate of cognitive decline among women who had low dietary intake at the baseline (below the median of 6·1 mg/d)( Reference Kang, Cook and Manson 60 ). These investigators performed similar post-hoc analyses for the Women's Antioxidant and Cardiovascular Study but using a much higher cut-off (15 mg/d) than in the Women's Health Study and found no effect of vitamin E supplementation( Reference Kang, Cook and Manson 58 ). This raises the possibility that the level of nutrient insufficiency for cognitive function is closer to 6 mg/d than to 15 mg/d. Populations vary considerably in vitamin E intake levels. For example, nearly the entire New York Washington Heights-Inwood Columbia Ageing Project study cohort was below 6 mg/d( Reference Luchsinger, Tang and Shea 44 ), whereas less than 20% of the Chicago Health and Ageing Project study cohort had intakes this low( Reference Morris, Evans and Bienias 54 ).

Although the epidemiological evidence for a protective relation of dietary β-carotene on dementia is weak, there is evidence from the randomised trials that higher levels consumed through vitamin supplementation over the long term may have protective benefits. In the Physicians’ Health Study, β-carotene supplementation (50 mg every other day) for 18 years significantly reduced the rate of cognitive decline, but there was no effect of the β-carotene supplement after 1 year of supplementation( Reference Grodstein, Kang and Glynn 59 ). Also, in post-hoc analyses of the Women's Antioxidant and Cardiovascular Health Study, women in the lowest quintile of total carotenoid intake at baseline (<3·09 mg/d) who were randomised to the β-carotene arm had statistically significantly slower rate of cognitive decline compared with the women in the placebo arm (P for interaction 0·02)( Reference Kang, Cook and Manson 58 ).

Plausible explanations for inconsistent findings for food and supplements

There are a number of differences between dietary and supplement sources of nutrient intake that could account for the positive findings for dietary intake and negative findings for supplemental intake. One difference is that the vitamin E form used in the supplement studies was high-dose α-tocopherol, usually twenty-five to fifty times the levels consumed through diet. The vitamin E measured in the dietary studies was not a single form but a combination of four tocopherols (α-, β-, δ- and γ- tocopherols) and their sterioisomers (α-, β-, δ- and γ- tocotrienols). α-Tocopherol has its own transfer protein that preferentially incorporates α-tocopherol into the plasma over other tocopherol forms. Consumption of high doses of α-tocopherol (e.g. through high-dose vitamin supplements) may not be functionally optimal. Studies have shown that consumption of high-dose α-tocopherol decreases the absorption of γ-tocopherol, a potent anti-inflammatory( Reference Yang, Lu and Ju 62 ) and that the highest level of antioxidant and anti-inflammatory action occurs with a combination of tocopherols( Reference Devaraj, Leonard and Traber 63 ). These studies highlight an important feature of diet which was not replicated in the vitamin supplement trials. Foods provide multiple dietary constituents at complementary dose levels to enhance absorption and metabolism for optimum physiological effect.

Lipids and dementia

Lipids comprise a broad group of molecules that include fatty acids (four classes: saturated, trans, polyunsaturated and monounsaturated) and cholesterols (LDL-cholesterol, HDL-cholesterol and TAG)( Reference Linscheer, Vergroesen, Shils, Olson and Shike 64 ). Their biological functions are concerned with energy storage, molecular signalling and as structural components of cell membranes( Reference Linscheer, Vergroesen, Shils, Olson and Shike 64 ). Most lipids can be synthesised by human subjects endogenously. The exceptions are two essential PUFA, α-linoleic acid (found in vegetable oils) and α-linolenic acid (found in flax seed, walnut and soya oils, nuts, seeds, wholegrains and seafood)( Reference Linscheer, Vergroesen, Shils, Olson and Shike 64 ). Dietary fat composition is one of the stronger predictors of blood lipid levels. A diet that is high in saturated and trans fats and low in polyunsaturated and monounsaturated fats results in a poor lipid profile of increased levels of LDL-cholesterol and TAG and decreased levels of HDL-cholesterol( Reference Keys and Parlin 65 Reference Mensink and Katan 67 ).

Biological mechanisms of lipids in dementia

Lipids represent the primary dry weight structure of the brain and the lipid, cholesterol, plays a central role in AD( Reference Puglielli, Tanzi and Kovacs 68 ). ApoE, a gene encoding cholesterol transport, is an established risk factor for AD in which the ApoE allele is associated with at least a doubling in risk( Reference Evans, Beckett and Field 69 , Reference Bennett, Wilson and Schneider 70 ). Depletion of brain cholesterol reduces the generation of amyloid β( Reference Simons, Keller and De Strooper 71 ). In animal models, a high-fat, hypercholesterolaemic diet has been shown to result in multiple deleterious effects on the brain including: significant amyloid β burden( Reference Sparks, Liu and Gross 72 Reference Howland, Trusko and Savage 74 ), phosphorylated τ( Reference Ullrich, Pirchl and Humpel 75 ), impaired cognition( Reference Ullrich, Pirchl and Humpel 75 Reference Sparks, Friedland and Petanceska 78 ), increased immunoreactivity( Reference Sparks, Liu and Gross 72 , Reference Ullrich, Pirchl and Humpel 75 ) and microglia activation( Reference Streit and Sparks 79 ) and decreased brain membrane fluidity and brain-derived neurotrophic factor( Reference Pistell, Morrison and Gupta 77 ). In contrast, animals fed diets enriched with corn oil (polyunsaturated fat) or olive oil (monounsaturated fat) had increased memory performance and activation of protein F1 ( Reference Wong, Murakami and Routtenberg 80 ).

Dietary fat composition and dementia

The epidemiological evidence for the association of dietary fat composition and dementia comes from several lines of evidence including dietary intake and biochemical levels of fatty acids, and blood lipid levels. The prospective epidemiological studies of dietary fat composition fairly consistently show increased risk of dementia and faster rate of cognitive decline with higher intakes of saturated fat( Reference Devore, Stampfer and Breteler 81 Reference Luchsinger, Min-Xing and Shea 87 ), although there are some negative studies( Reference Engelhart, Geerlings and Ruitenberg 88 , Reference Samieri, Feart and Letenneur 89 ). The limited number of prospective studies that investigated the association of trans fat intake found increased dementia risk( Reference Devore, Stampfer and Breteler 81 , Reference Morris, Evans and Bienias 84 , Reference Morris, Evans and Bienias 85 ). Studies of polyunsaturated and monounsaturated fat intakes are very inconsistent with some finding inverse associations( Reference Devore, Stampfer and Breteler 81 , Reference Beydoun, Kaufman and Satia 83 , Reference Morris, Evans and Bienias 84 , Reference Solfrizzi, Colacicco and D'Introno 90 ) and others no association( Reference Eskelinen, Ngandu and Helkala 82 , Reference Heude, Ducimetiere and Berr 86 Reference Samieri, Feart and Letenneur 89 ) with dementia outcomes. One complicating factor in the interpretation of these studies is that intakes of ‘healthy fats’ (polyunsaturated and monounsaturated) are positively correlated with intakes of the unhealthy fats (saturated and trans). This can result in considerable negative confounding (i.e. confounding in the opposite direction of the true relation) that likely obscured real associations. Very few of these studies analysed the different dietary fats conjointly in the statistical analyses. Those that did control for intakes of other fats found inverse associations of polyunsaturated and monounsaturated fats with incident AD( Reference Morris, Evans and Bienias 84 ) and cognitive decline( Reference Devore, Stampfer and Breteler 81 , Reference Morris, Evans and Bienias 85 ). Even so, the evidence for associations of polyunsaturated and monounsaturated fats in and of themselves is weak for dementia outcomes. It could be that the composition of the diet towards a higher ratio of unsaturated to saturated fats is what is most important for protection against dementia; of four studies that examined this relation( Reference Devore, Stampfer and Breteler 81 , Reference Eskelinen, Ngandu and Helkala 82 , Reference Morris, Evans and Bienias 84 , Reference Morris, Evans and Bienias 85 ), three found inverse associations( Reference Devore, Stampfer and Breteler 81 , Reference Morris, Evans and Bienias 84 , Reference Morris, Evans and Bienias 85 ).

Examination of the prospective blood lipid studies reveal an interesting pattern from middle-to-late adulthood in which, overall, blood cholesterol levels decrease with older age but the highest rate of decrease occurs among those who had the highest cholesterol levels in mid-life( Reference Ferrara, Barrett-Connor and Shan 91 , Reference Solomon, Kareholt and Ngandu 92 ). Studies relating mid-life cholesterol to late-life dementia have shown that compared with non-demented individuals, those who become demented exhibit a greater decrease in blood cholesterol level with older age( Reference Solomon, Kareholt and Ngandu 92 ). The same phenomenon has been demonstrated in longitudinal studies of blood pressure( Reference Skoog, Lernfelt and Landahl 13 ) and weight( Reference Whitmer, Gunderson and Barrett-Connor 15 ). This may explain why most studies that examined blood cholesterol in mid-life have observed positive associations with the risk of dementia in late life( Reference Kivipelto, Helkala and Laakso 14 , Reference Beydoun, Beason-Held and Kitner-Triolo 22 , Reference Solomon, Kareholt and Ngandu 92 Reference Notkola, Sulkava and Pekkanen 97 ), but findings of studies that examined cholesterol levels in late life are either null( Reference Yaffe, Weston and Blackwell 20 , Reference Rastas, Pirttila and Mattila 98 , Reference Li, Shofer, Kukull and Peskind 99 ) or inconsistent with some showing positive associations with dementia risk( Reference Yaffe, Barrett-Connor and Lin 100 , Reference Moroney, Tang and Berglund 101 ) and others showing inverse associations( Reference Reitz, Tang and Manly 102 , Reference Romas, Tang and Berglund 103 ). One plausible explanation may be that the disease process of dementia accelerates the decreases with older age in levels of cholesterol, blood pressure and weight.

n-3 Fatty acids and the brain

The n-3 fatty acids are a class of polyunsaturated fat that includes three nutritionally important species: α-linolenic acid (18:3 n-3), EPA (20:5 n-3) and DHA (22:6 n-3). Mammals cannot synthesise α-linolenic acid and so it must be consumed through oils (e.g. soyabean, flaxseed, black currant and rapeseed) wheat germ, soyabeans, or nuts (e.g. walnuts). In human subjects, α-linolenic acid is elongated and desaturated to form EPA and DHA, but this conversion is not more than 0·5%( Reference Harris, Mozaffarian and Lefevre 104 ). Fish and seafood are a direct natural dietary source of DHA and EPA, although eggs and meats can also contain these n-3 fatty acids in animals with supplemented feed or who graze on certain grasses that contain α-linolenic acid.

DHA primary lipid in metabolically active brain regions

DHA is the primary n-3 fatty acid in the brain; other species of n-3 fatty acids are uncommonly found( Reference Connor 105 ). DHA is the predominant lipid in the most metabolically active areas of the brain including the cerebral cortex, synaptosomes and mitochondria( Reference Carrie, Clement and de Javel 106 , Reference Connor, Neuringer and Lin 107 ). In laboratory studies, animals fed diets enriched with n-3 PUFA had superior learning acquisition and memory performance( Reference Carrie, Clement and de Javel 106 , Reference Gamoh, Hashimoto and Sugioka 108 Reference Yamamoto, Saitoh and Moriuchi 116 ) including in aged mice( Reference Suzuki, Park and Tamura 109 , Reference Gamoh, Hashimoto and Hossain 117 Reference Sugimoto, Taga and Nishiga 119 ), better regulation of neuronal membrane excitability( Reference Itokazu, Ikegaya and Nishikawa 120 Reference Young, Gean and Chiou 125 ), increased levels of neurotransmitters and receptors( Reference Chalon, Delion-Vancassel and Belzung 126 Reference Innis 129 ), increased hippocampal nerve growth( Reference Ikemoto, Nitta and Furukawa 130 ), greater fluidity of synaptic membranes( Reference Suzuki, Park and Tamura 109 ) and reduced ischaemic damage to neurons( Reference Okada, Amamoto and Tomonaga 131 ).

Cardiovascular mechanisms of fish protection

Fish and n-3 fatty acids have favourable effects on the cardiovascular system including lower blood pressure, lower TAG and reduced cardiac death (one fish meal per week)( Reference Harris, Mozaffarian and Lefevre 104 ). In a meta-analysis of nine prospective studies of incident stroke there was a dose–response inverse association with increased fish consumption( Reference He, Song and Daviglus 132 ). Thus, in addition to the earlier-described mechanisms of DHA on brain health, dietary fish consumption may be protective particularly of vascular dementia through their beneficial effects on these cardiovascular risk factors.

Epidemiological evidence for fish and n-3 fatty acids and dementia

In prospective studies, consumption of fish was associated with lower risk of incident dementia( Reference Barberger-Gateau, Letenneur and Deschamps 133 Reference Larrieu, Letenneur and Helmer 138 ), stroke( Reference Gillum, Mussolino and Madans 139 , Reference Iso, Rexrode and Stampfer 140 , Reference Keli, Feskens and Kromhout 141 , Reference Orencia, Daviglus and Dyer 142 ), and cognitive decline( Reference Heude, Ducimetiere and Berr 86 , Reference Morris, Evans and Tangney 143 ). A number of studies investigated the relation of fish intake to risk of developing AD. In all cases, the estimated OR were in the protective direction and most were statistically significant at a low level of intake of just one fish meal per week( Reference Barberger-Gateau, Letenneur and Deschamps 133 Reference Larrieu, Letenneur and Helmer 138 ,Reference Devore, Grodstein and van Rooij 144 ). The Rotterdam Study reported significant reduction in risk after 2·1 years of follow-up( Reference Kalmijn, Launer and Ott 135 ), but the association after 9 years was not statistically significant( Reference Devore, Grodstein and van Rooij 144 ). One plausible explanation for these discrepant findings may be misclassification error in the dietary exposure as diet was not reassessed to capture potential changes in fish consumption over the 9-year period. Two of the studies observed the inverse association with dementia only among persons who were apoE-ε4 negative( Reference Huang, Zandi and Tucker 134 , Reference Barberger-Gateau, Raffaitin and Letenneur 145 ), but this was not observed in other studies( Reference Kalmijn, Launer and Ott 135 Reference Larrieu, Letenneur and Helmer 138 ,Reference Devore, Grodstein and van Rooij 144 ). Of interest, the relation of fish consumption to AD risk in the Cardiovascular Health Study was specific to fatty fish and not to fried fish( Reference Huang, Zandi and Tucker 134 ). This raises the question of whether fish preparation might alter the neuroprotective benefit given that frying reduces the n-3 fatty acid levels and increases saturated fat intake. In the Women's Health Initiative Observational Study, women who consumed five or more servings per week of baked or broiled fish had a 30% reduction in the risk of incident heart failure, whereas women who consumed one or more weekly servings of fried fish had an increase in risk (hazard ratio 1·5, 95% CI 7·2, 1·8)( Reference Belin, Greenland and Martin 146 ).

A few randomised trials on the effects of DHA supplements on cognitive decline reported negative findings. A major flaw in the designs of these trials( Reference Quinn, Raman and Thomas 147 , Reference van de Rest, Geleijnse and Kok 148 ) is that they allowed fish consumption up to three fish meals per week among all trial participants. This is far above the level (one fish meal per week) that was observed to be inversely associated with dementia in the majority of epidemiological studies. As a result, the difference between treatment and placebo groups in intake levels at the level of benefit may have been minimised thus resulting in null findings of the supplement.

Several studies examined the relation between fish consumption and decline in cognitive test scores with two studies showing statistically significant reductions at just one fish meal per week( Reference Morris, Evans and Tangney 143 , Reference van Gelder, Tijhuis and Kalmijn 149 ), whereas the third study was null( Reference van de Rest, Geleijnse and Kok 148 ). Neither of the two positive studies observed statistically significant inverse associations with dietary intake levels of the marine n-3 fatty acids( Reference Morris, Evans and Tangney 143 , Reference van Gelder, Tijhuis and Kalmijn 149 ). However, of the six studies that measured biochemical levels of n-3 fatty acids, three observed statistically significant reductions in the rate of cognitive decline( Reference Beydoun, Kaufman and Satia 83 , Reference Heude, Ducimetiere and Berr 86 , Reference Whalley, Deary and Starr 150 ) and two others observed inverse associations with dementia( Reference Samieri, Feart and Letenneur 89 , Reference Schaefer, Bongard and Beiser 137 ). The apparent inconsistency may be due to the fact that food frequency assessment of marine n-3 fatty acid intake is relatively imprecise. This is because most questionnaires employ at most three general questions on fish consumption and thus do not capture well the different levels of EPA and DHA contained in different types of fish. Correlations between dietary levels of the n-3 fatty acids and biochemical levels are typically about 0·35( Reference Hunter and Willett 151 ).

B-vitamins and the brain

Among the B-vitamins, the two that have received the greatest attention for brain health in the scientific literature are vitamin B9 (folate) and vitamin B12 (cobalamin). These are co-factor nutrients that are known to affect neurocognitive development and neurodegeneration. The importance of adequate folate intake in the first trimester of pregnancy to prevent congenital neural tube defects is now well established( Reference Molloy and Scott 152 ). This prompted the United States Department of Agriculture to mandate fortification of the grain supply in 1998 with folic acid at 140 μg per 100 g grain( Reference Quinivan and Gregory 153 ). The prevalence of low-serum folate has since decreased from 16–22% pre-fortification to 0·5–1·7% post-fortification( Reference Kalmbach, Choumenkovitch and Troen 154 ). This required level of fortification was considered generally safe; however, controversy still exists regarding the safety for population subgroups like the elderly.

Vitamin B12 and folate: cofactors in metabolic pathways

Vitamin B12 and folate have essential and intertwined roles in human health as they are co-factors in the metabolism of DNA and erythrocytes synthesis and with methionine and S-adenosylmethionine synthesis. Both vitamin B12 and folate (5-methyl-tetrahydrofolate (THF)) are required for the remethylation of homocysteine to methionine, while simultaneously demethylating 5-methyl-THF to THF( Reference Herbert, Das, Shils, Olson and Shike 155 ). Thus, with vitamin B12 deficiency, there is an accumulation of homocysteine and 5-methyl-THF. Vitamin B12 deficiency syndrome is characterised by peripheral neuropathy, megaloblastic anaemia, fatigue, depression and cognitive impairment( Reference Savage and Lindenbaum 156 ). The neuropathy characteristic of vitamin B12 deficiency is probably the result of the block in this pathway because myelin basic protein is ‘hypomethylated’. The typical haematological manifestations of vitamin B12 and folate deficiency (megaloblastic anaemia and granulocyte hypersegmentation) are thought to be the result of a reduction in DNA synthesis when 5,10-methylene-THF is lacking. Synthetic folic acid may correct this problem if the tissue contains an enzyme that can reduce folic acid to THF.

B-vitamins, cognitive decline and Alzheimer's disease

Epidemiologic studies and randomised clinical trials on the international scene for B-vitamins and cognition have produced seemingly inconsistent findings that may reflect the complex interrelation of vitamin B12 and folate in the metabolic pathways as well as differences among study populations in vitamin deficiencies, vitamin supplementation and food fortification. An important public health issue is whether or under what conditions, B-vitamin supplementation and food fortification are of benefit or harm to older persons. Vitamin B12 deficiency is common in older adults( Reference Carmel 157 , Reference Pfeiffer, Caudill and Gunter 158 ). Folate deficiency, on the other hand, is now a rare occurrence in the USA since the folic acid fortification( Reference Kalmbach, Choumenkovitch and Troen 154 ).

In recent years, there has been a lot of interest in vitamin B12 and folate as risk factors for dementia. This interest is largely based on their relations as co-factors in the metabolism of homocysteine. Homocysteine has been related to the risk of developing AD in some( Reference Seshadri, Beiser and Selhub 159 , Reference Haan, Miller and Aiello 160 ) but not all studies( Reference Luchsinger, Tang and Shea 161 ) and remains a topic of interest. The mechanism for association is not known, although homocysteine and folate deficiency have been shown to be neurotoxic in mouse models of AD( Reference Ho, Collins and Dhitavat 162 , Reference Tchantchou and Shea 163 ).

Commonly, observational studies and randomised trials that examine nutrient effects on disease processes do not consider dose level when interpreting study results and trial design and, as noted earlier, this consideration is particularly important for folate because of folic acid fortification in some countries. Populations will also differ in vitamin B12 nutriture depending on the prevalence of atrophic gastritis and the use of medications that affect gastric acidity in addition to dietary and supplemental intake. Thus, some of the inconsistent findings across studies of B-vitamin effects on cognitive decline and dementia may be due to the range of nutrient status in the study population. Of ten cohort studies that examined the relations of these B-vitamins and cognitive decline, four reported protective associations with folate( Reference Mooijaart, Gussekloo and Frolich 164 Reference Kim, Kim and Shin 167 ) and three reported protective associations with vitamin B12 ( Reference Tucker, Qiao and Scott 165 , Reference Morris, Evans and Bienias 168 Reference Clarke, Birks and Nexo 170 ) but many found no association with one or the other B-vitamin( Reference Tucker, Qiao and Scott 165 , Reference Clarke, Birks and Nexo 170 Reference McCaddon, Hudson and Abrahamsson 174 ). The Chicago Health and Ageing Project study found a deleterious effect of faster decline among persons with food and/or supplement intakes exceeding 400 μg/d( Reference Hebert, Beckett and Scherr 6 ). This USA study took place primarily post-fortification. The deleterious findings with high levels of folic acid were also reported in a cross-sectional study of National Health and Nutrition Examination Survey data( Reference Morris, Jacques and Rosenberg 175 ) in which persons with low vitamin B12 status and elevated serum folate concentrations were more likely to manifest impaired cognitive performance than those with normal serum folate concentrations.

A number of prospective studies that examined the relation between folate and dementia found inverse associations( Reference Luchsinger, Tang and Miller 176 Reference Kim, Stewart and Kim 180 ), although several studies did not( Reference Seshadri, Beiser and Selhub 159 , Reference Morris, Evans and Bienias 181 , Reference Nelson, Wengreen and Munger 182 ). In contrast, the studies that examined the association of vitamin B12 with AD were null( Reference Seshadri, Beiser and Selhub 159 , Reference Luchsinger, Tang and Miller 176 Reference Corrada, Kawas and Hallfrisch 178 , Reference Kim, Stewart and Kim 180 Reference Nelson, Wengreen and Munger 182 ). There have been a number of randomised trials of the effects of supplementation with folic acid and vitamin B12 on cognitive decline. Most of the trials included a small number of subjects and supplemented over short periods of weeks or months, thus making it difficult to interpret the null results. Of several large randomised trials that tested B-vitamin supplementation for longer periods of time (i.e. 2–10 years)( Reference Durga, van Boxtel and Schouten 183 Reference Kang, Cook and Manson 186 ), only one( Reference Durga, van Boxtel and Schouten 183 ) targeted individuals who had low folate status. In this trial, after 3 years of folic acid supplementation, the treated group had a statistically significant slower rate of cognitive decline compared with the placebo group( Reference Durga, van Boxtel and Schouten 183 ). In another randomised trial of folic acid, vitamin B12 and vitamin B6 supplementation in older persons with high homocysteine (VITACOG and ISRCTN 94410159), 2 years of treatment reduced decline in global cognition and in memory( Reference de Jager, Oulhaj and Jacoby 184 ). Treated subjects in this trial also had evidence of reduced brain atrophy compared with participants taking placebo( Reference Smith, Smith and de Jager 187 ). Two other trials tested a combination therapy of folate, vitamin B12 and vitamin B6 on cognitive decline and found no effect overall( Reference McMahon, Green and Skeaff 185 , Reference Kang, Cook and Manson 186 ). It is noteworthy that post-hoc analyses of one of these negative trials( Reference Kang, Cook and Manson 186 ) found protective effects of the B-vitamin supplement among women who had low B-vitamin intake at baseline.

In summary, based on the current available evidence, insufficient levels of vitamin B12 and folate may be associated with faster cognitive decline. While there is some evidence to support that insufficient folate may also increase the risk of developing AD this is not the case for vitamin B12. In addition, there is a possibility that exposure to high levels of folic acid in vitamin supplements or fortified food may be also associated with cognitive decline. In view of the folate fortification policy in some countries, this needs to be investigated further. Mandatory food fortification and vitamin supplementation have resulted in unprecedented numbers of persons with high circulating folic acid concentrations in the USA( Reference Pfeiffer, Caudill and Gunter 158 ). This substantially raises the potential for misdiagnosis of subtle vitamin B12 deficiency and increases prevalence of its neurologic syndrome. Masking of vitamin B12 deficiency can occur when there is correction of the macrocytic anaemia but not of the neurologic consequences. In case reports nearly five decades ago, folic acid treatment of vitamin B12-deficient individuals was reported to aggravate neurological complications( Reference Savage and Lindenbaum 156 , Reference Chodos and Ross 188 ). These older reports gain greater importance in light of the recent Chicago Health and Ageing Project and National Health and Nutrition Examination Survey studies( Reference Morris, Evans and Bienias 168 , Reference Morris, Jacques and Rosenberg 175 ). The possible adverse outcomes cannot be ignored in the face of the prevalence of subtle vitamin B12 deficiency and the dramatic increase in folate intake that has occurred in the USA and other countries that have mandatory fortification.

Conclusion

The available evidence from laboratory, animal and epidemiological studies shows promise for protection against cognitive decline and dementia through a number of dietary components. The strongest, most consistent evidence is for dietary intakes of vitamin E, fish and n-3 fatty acids, high ratio of polyunsaturated to saturated fats, and the B-vitamins, particularly folate and vitamin B12. These dietary components are prominent in the Mediterranean diet that is high in vegetables, fruits, fish, whole grains, legumes and monounsaturated oils, and low in meats and high-fat dairy. Several prospective studies reported protective associations of adherence to the Mediterranean diet with cognitive decline( Reference Scarmeas, Stern and Mayeux 189 Reference Tangney, Kwasny and Li 191 ) and dementias( Reference Scarmeas, Stern and Mayeux 192 ). The studies on vitamin E and B-vitamins suggest that it is low intake or low vitamin status that are deleterious for brain function and health. That is, persons with adequate vitamin status may not benefit further from vitamin supplemental intake. Few randomised clinical trials are designed to test these observed relations from the epidemiological studies. The trial participants are generally recruited without regard to nutrient intake or vitamin status, and all participants are allowed to take multivitamins (or consume fish in DHA supplement trials), thus further diluting a potential treatment effect. To most appropriately test the effect of nutrients on brain-related conditions, randomised clinical trials need to target individuals who have less than adequate nutrient status. The field of diet and neurodegenerative diseases is still very young. Much further research is needed to understand the roles of different dietary components in the aging brain and also their interactions among each other, with genetic risk factors and with various conditions.

Acknowledgements

The author declares no conflicts of interest.

References

1. Brewer, JB, Gabrieli, JDE, Preston, AR et al. (2007) Memory. In Textbook of Clinical Neurology , 3rd ed. [Goestz, CG]. Philadelphia, PA: Saunders Elsevier.Google Scholar
2. Evans, DA, Funkenstein, HH, Albert, MS et al. (1989) Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262, 25512556.CrossRefGoogle Scholar
3. Bennett, DA (2000) Part II. Clinical diagnosis and course of Alzheimer's disease. Dis Mon 46, 666686.CrossRefGoogle ScholarPubMed
4. Schneider, JA, Arvanitakis, Z, Bang, W et al. (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 21972204.CrossRefGoogle ScholarPubMed
5. Hebert, LE, Scherr, PA, Bienias, JL et al. (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60, 11191122.CrossRefGoogle ScholarPubMed
6. Hebert, LE, Beckett, LA, Scherr, PA et al. (2001) Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 15, 169173.CrossRefGoogle Scholar
7. McKhann, G, Drachman, D, Folstein, M et al. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939944.CrossRefGoogle ScholarPubMed
8. Anonymous (1985) Criteria for the clinical diagnosis of Alzheimer's disease. Excerpts from the NINCDS-ADRDA Work Group report. J Am Geriatr Soc 33, 23.CrossRefGoogle Scholar
9. Reitz, C, Brayne, C & Mayeux, R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7, 137152.CrossRefGoogle ScholarPubMed
10. Davidglus, M, Bell, C, Berrettini, W et al. (2010) National Institutes of Health State-of-the-Science Conference Statement: Preventing Alzhiemer's Disease and Cognitive Decline. NIH Consensus State-of-the-Science Statements, p. 130.Google Scholar
11. Larson, EB, Wang, L, Bowen, JD et al. (2010) Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 144, 7381.CrossRefGoogle Scholar
12. Luchsinger, JA, Noble, JM & Scarmeas, N (2007) Diet and Alzheimer's disease. Curr Neurol Neurosci Rep 7, 366372.CrossRefGoogle ScholarPubMed
13. Skoog, I, Lernfelt, B, Landahl, S et al. (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 11411145.CrossRefGoogle ScholarPubMed
14. Kivipelto, M, Helkala, EL, Laakso, MP et al. (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137, 149155.CrossRefGoogle ScholarPubMed
15. Whitmer, RA, Gunderson, EP, Barrett-Connor, E et al. (2005) Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. Br Med J 330, 1360.CrossRefGoogle ScholarPubMed
16. Luchsinger, JA, Tang, MX, Stern, Y et al. (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154, 635641.CrossRefGoogle Scholar
17. Reitz, C, Brickman, AM, Luchsinger, JA et al. (2007) Frequency of subclinical heart disease in elderly persons with dementia. Am J Geriatr Cardiol 16, 183188.CrossRefGoogle ScholarPubMed
18. Schneider, JA, Wilson, RS, Bienias, JL et al. (2004) Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 62, 11481155.CrossRefGoogle ScholarPubMed
19. Kalmijn, S, Foley, D, White, L et al. (2000) Metabolic cardiovascular syndrome and risk of dementia in Japanese–American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 20, 22552260.CrossRefGoogle ScholarPubMed
20. Yaffe, K, Weston, AL, Blackwell, T et al. (2009) The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 66, 324328.CrossRefGoogle ScholarPubMed
21. Solomon, A, Kareholt, I, Ngandu, T et al. (2009) Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging 30, 10061009.CrossRefGoogle ScholarPubMed
22. Beydoun, MA, Beason-Held, LL, Kitner-Triolo, MH et al. (2010) Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health 65, 949957.CrossRefGoogle ScholarPubMed
23. t'Veld, BA, Ruitenberg, A, Hofman, A et al. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345, 15151521.CrossRefGoogle Scholar
24. Bekris, LM, Yu, CE, Bird, TD et al. (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23, 213227.CrossRefGoogle ScholarPubMed
25. Morris, MC, Evans, DA, Hebert, LE et al. (1999) Methodological issues in the study of cognitive decline. Am J Epidemiol 149, 789793.CrossRefGoogle Scholar
26. Spector, R (2009) Nutrient transport systems in brain: 40 years of progress. J Neurochem 111, 315320.CrossRefGoogle ScholarPubMed
27. Spector, R (2010) Nature and consequences of mammalian brain and CSF efflux transporters: Four decades of progress. J Neurochem 112, 1323.CrossRefGoogle ScholarPubMed
28. Pardridge, WM (1998) Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res 23, 635644.CrossRefGoogle ScholarPubMed
29. Muller, D (1995) Vitamin E and neurological function: Lessons from patients with abetalipoproteinaemia. Redox Rep 1, 239245.CrossRefGoogle ScholarPubMed
30. Muller, DP, Lloyd, JK & Wolff, OH (1983) Vitamin E and neurological function: Abetalipoproteinaemia and other disorders of fat absorption. Ciba Found Symp 101, 106121.Google ScholarPubMed
31. Koscik, RL, Farrell, PM, Kosorok, MR et al. (2004) Cognitive function of children with cystic fibrosis: Deleterious effect of early malnutrition. Pediatrics 113, 15491558.CrossRefGoogle ScholarPubMed
32. Morris, MC & Tangney, CC (2011) A potential design flaw of randomized trials of vitamin supplements. JAMA 305, 13481349.CrossRefGoogle ScholarPubMed
33. Blumberg, J, Heaney, RP, Huncharek, M et al. (2010) Evidence-based criteria in the nutritional context. Nutr Rev 68, 478484.CrossRefGoogle ScholarPubMed
34. Mecocci, P, MacGarvey, U, Kaufman, AE et al. (1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 34, 609616.CrossRefGoogle ScholarPubMed
35. Bishop, NA, Lu, T & Yankner, BA (2010) Neural mechanisms of ageing and cognitive decline. Nature 464, 529535.CrossRefGoogle ScholarPubMed
36. Haigis, MC & Yankner, BA (2010) The aging stress response. Mol Cell 40, 333344.CrossRefGoogle ScholarPubMed
37. Christen, Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71, 621S629S.CrossRefGoogle ScholarPubMed
38. Jenner, P (1994) Oxidative damage in neurodegenerative disease. Lancet 344, 68.CrossRefGoogle ScholarPubMed
39. Mecocci, P, MacGarvey, U & Beal, MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36, 747751.CrossRefGoogle ScholarPubMed
40. Beal, MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991, 120131.CrossRefGoogle ScholarPubMed
41. Sardesai, VM (1995) Role of antioxidants in health maintenance. Nutr Clin Pract 10, 1925.CrossRefGoogle ScholarPubMed
42. Olanow, CW (1990) Oxidation reactions in Parkinson's disease. Neurology 40, 10 Suppl 3, S-7.Google ScholarPubMed
43. Koscik, RL, Lai, HJ, Laxova, A et al. (2005) Preventing early, prolonged vitamin E deficiency: An opportunity for better cognitive outcomes via early diagnosis through neonatal screening. J Pediatr 147, 3 Suppl., S51S56.CrossRefGoogle ScholarPubMed
44. Luchsinger, JA, Tang, MX, Shea, S et al. (2003) Antioxidant vitamin intake and risk of Alzheimer's disease. Arch Neurol 60, 203208.CrossRefGoogle Scholar
45. Engelhart, MJ, Geerlings, MI, Ruitenberg, A et al. (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287, 32233229.CrossRefGoogle ScholarPubMed
46. Ravaglia, G, Forti, P, Lucicesare, A et al. (2008) Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. Am J Clin Nutr 87, 13061313.CrossRefGoogle Scholar
47. Mangialasche, F, Kivipelto, M, Mecocci, P et al. (2010) High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. J Alzheimers Dis 20, 10291037.CrossRefGoogle ScholarPubMed
48. Kang, JH & Grodstein, F (2008) Plasma carotenoids and tocopherols and cognitive function: A prospective study. Neurobiol Aging 29, 13941403.CrossRefGoogle ScholarPubMed
49. Helmer, C, Peuchant, E, Letenneur, L et al. (2003) Association between antioxidant nutritional indicators and the incidence of dementia: Results from the PAQUID prospective cohort study. Eur J Clin Nutr 57, 15551561.CrossRefGoogle ScholarPubMed
50. Zandi, PP, Anthony, JC, Khachaturian, AS et al. (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 61, 8288.CrossRefGoogle ScholarPubMed
51. Devore, EE, Grodstein, F, van Rooij, FJ et al. (2010) Dietary antioxidants and long-term risk of dementia. Arch Neurol 67, 819825.CrossRefGoogle ScholarPubMed
52. Fillenbaum, GG, Kuchibhatla, MN, Hanlon, JT et al. (2005) Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann Pharmacother 39, 20092014.CrossRefGoogle ScholarPubMed
53. Laurin, D, Foley, DJ, Masaki, KH et al. (2002) Vitamin E and C supplements and risk of dementia. JAMA 288, 22662268.CrossRefGoogle Scholar
54. Morris, MC, Evans, DA, Bienias, JL et al. (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer's disease in a biracial community study. JAMA 287, 32303237.CrossRefGoogle Scholar
55. Morris, MC, Evans, DA, Bienias, JL et al. (2002) Vitamin E and cognitive decline in older persons. Arch Neurol 59, 11251132.CrossRefGoogle ScholarPubMed
56. Gray, SL, Anderson, ML, Crane, PK et al. (2008) Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J Am Geriatr Soc 56, 291295.CrossRefGoogle ScholarPubMed
57. Maxwell, CJ, Hicks, MS, Hogan, DB et al. (2005) Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord 20, 4551.CrossRefGoogle ScholarPubMed
58. Kang, JH, Cook, NR, Manson, JE et al. (2009) Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study. Circulation 119, 27722780.CrossRefGoogle ScholarPubMed
59. Grodstein, F, Kang, JH, Glynn, RJ et al. (2007) A randomized trial of beta carotene supplementation and cognitive function in men: The Physicians’ Health Study II. Arch Intern Med 167, 21842190.CrossRefGoogle ScholarPubMed
60. Kang, JH, Cook, N, Manson, J et al. (2006) A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 166, 24622468.CrossRefGoogle ScholarPubMed
61. Petersen, RC, Thomas, RG, Grundman, M et al. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352, 23792388.CrossRefGoogle ScholarPubMed
62. Yang, CS, Lu, G, Ju, J et al. (2010) Inhibition of inflammation and carcinogenesis in the lung and colon by tocopherols. Ann NY Acad Sci 1203, 2934.CrossRefGoogle Scholar
63. Devaraj, S, Leonard, S, Traber, MG et al. (2008) Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med 44, 12031208.CrossRefGoogle ScholarPubMed
64. Linscheer, WG & Vergroesen, AJ. (1994) Lipids. In Modern Nutrition in Health and Disease , p. 4788 [Shils, M, Olson, JA & Shike, M]. Philadelphia: Lea &Febige.Google Scholar
65. Keys, A & Parlin, RW (1966) Serum cholesterol response to changes in dietary lipids. Am J Clin Nutr 19, 175181.CrossRefGoogle ScholarPubMed
66. Brouwer, IA, Wanders, AJ & Katan, MB (2010) Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans – a quantitative review. PLoS ONE 5, e9434.CrossRefGoogle ScholarPubMed
67. Mensink, RP & Katan, MB (1991) Effect of dietary fatty acids on serum lipids and lipoproteins: A meta-analysis of 27 trials. Arterioscler Thromb 12, 911912.CrossRefGoogle Scholar
68. Puglielli, L, Tanzi, R & Kovacs, D (2003) Alzheimer's disease: The cholesterol connection. Nat Neurosci 6, 345351.CrossRefGoogle ScholarPubMed
69. Evans, DA, Beckett, LA, Field, TS et al. (1997) Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA 277, 822824.CrossRefGoogle Scholar
70. Bennett, DA, Wilson, RS, Schneider, JA et al. (2003) Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 60, 246252.CrossRefGoogle ScholarPubMed
71. Simons, M, Keller, P, De Strooper, B et al. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95, 64606464.CrossRefGoogle ScholarPubMed
72. Sparks, DL, Liu, H, Gross, DR et al. (1995) Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol. Neurosci Lett 187, 142144.CrossRefGoogle ScholarPubMed
73. Walker, LC, Parker, CA, Lipinski, WJ et al. (1997) Cerebral lipid deposition in aged apolipoprotein-E-deficient mice. Am J Pathol 151, 13711377.Google ScholarPubMed
74. Howland, DS, Trusko, SP, Savage, MJ et al. (1998) Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem 273, 1657616582.CrossRefGoogle ScholarPubMed
75. Ullrich, C, Pirchl, M & Humpel, C (2010) Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 45, 408417.CrossRefGoogle ScholarPubMed
76. Greenwood, CE & Winocur, G (1996) Cognitive impairment in rats fed high-fat diets: A specific effect of saturated fatty-acid intake. Behav Neurosci 110, 451459.CrossRefGoogle ScholarPubMed
77. Pistell, PJ, Morrison, CD, Gupta, S et al. (2010) Cognitive impairment following high fat diet consumption is associated with brain inflammation. J Neuroimmunol 219, 2532.CrossRefGoogle ScholarPubMed
78. Sparks, DL, Friedland, R, Petanceska, S et al. (2006) Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging 10, 247254.Google ScholarPubMed
79. Streit, WJ & Sparks, DL (1997) Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med 75, 130138.CrossRefGoogle ScholarPubMed
80. Wong, KL, Murakami, K & Routtenberg, A (1989) Dietary cis-fatty acids that increase protein F1 phosphorylation enhance spatial memory. Brain Res 505, 302305.CrossRefGoogle ScholarPubMed
81. Devore, EE, Stampfer, MJ, Breteler, MM et al. (2009) Dietary fat intake and cognitive decline in women with type 2 diabetes. Diabetes Care 32, 635640.CrossRefGoogle ScholarPubMed
82. Eskelinen, MH, Ngandu, T, Helkala, EL et al. (2008) Fat intake at midlife and cognitive impairment later in life: A population-based CAIDE study. Int J Geriatr Psychiatry 23, 741747.CrossRefGoogle ScholarPubMed
83. Beydoun, MA, Kaufman, JS, Satia, JA et al. (2007) Plasma n-3 fatty acids and the risk of cognitive decline in older adults: The atherosclerosis risk in communities study. Am J Clin Nutr 85, 11031111.CrossRefGoogle ScholarPubMed
84. Morris, MC, Evans, DA, Bienias, JL et al. (2003) Dietary fats and the risk of incident Alzheimer's disease. Arch Neurol 60, 194200.CrossRefGoogle Scholar
85. Morris, MC, Evans, DA, Bienias, JL et al. (2004) Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology 62, 15731579.CrossRefGoogle Scholar
86. Heude, B, Ducimetiere, P & Berr, C (2003) Cognitive decline and fatty acid composition of erythrocyte membranes – The EVA study. Am J Clin Nutr 77, 803808.CrossRefGoogle ScholarPubMed
87. Luchsinger, JA, Min-Xing, T, Shea, S et al. (2002) Caloric intake and the risk of Alzheimer disease. Arch Neurol 59, 12581263.CrossRefGoogle ScholarPubMed
88. Engelhart, MJ, Geerlings, MI, Ruitenberg, A et al. (2002) Diet and risk of dementia: Does fat matter? Neurology 59, 19151921.CrossRefGoogle ScholarPubMed
89. Samieri, C, Feart, C, Letenneur, L et al. (2008) Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr 88, 714721.CrossRefGoogle ScholarPubMed
90. Solfrizzi, V, Colacicco, AM, D'Introno, A et al. (2006) Dietary intake of unsaturated fatty acids and age-related cognitive decline: A 8·5-year follow-up of the Italian Longitudinal Study on Aging. Neurobiol Aging 27, 16941704.CrossRefGoogle ScholarPubMed
91. Ferrara, A, Barrett-Connor, E & Shan, J (1997) Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984–1994. Circulation 96, 3743.CrossRefGoogle Scholar
92. Solomon, A, Kareholt, I, Ngandu, T et al. (2007) Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study. Neurology 68, 751756.CrossRefGoogle ScholarPubMed
93. Whitmer, RA, Sidney, S, Selby, J et al. (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277281.CrossRefGoogle ScholarPubMed
94. Reynolds, CA, Gatz, M, Prince, JA et al. (2010) Serum lipid levels and cognitive change in late life. J Am Geriatr Soc 58, 501509.CrossRefGoogle ScholarPubMed
95. Solomon, A, Kivipelto, M, Wolozin, B et al. (2009) Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 28, 7580.CrossRefGoogle ScholarPubMed
96. Mainous, AG III, Eschenbach, SL, Wells, BJ et al. (2005) Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: Results from an 18-year population-based cohort. Fam Med 37, 3642.Google ScholarPubMed
97. Notkola, IL, Sulkava, R, Pekkanen, J et al. (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17, 1420.CrossRefGoogle ScholarPubMed
98. Rastas, S, Pirttila, T, Mattila, K et al. (2010) Vascular risk factors and dementia in the general population aged >85 years: Prospective population-based study. Neurobiol Aging 31, 17.CrossRefGoogle ScholarPubMed
99. Li, G, Shofer, JB, Kukull, WA, Peskind, ER et al. (2005) Serum cholesterol and risk of Alzheimer disease: A community-based cohort study. Neurology 65, 10451050.CrossRefGoogle ScholarPubMed
100. Yaffe, K, Barrett-Connor, E, Lin, F et al. (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59, 378384.CrossRefGoogle ScholarPubMed
101. Moroney, JT, Tang, MX, Berglund, L et al. (1999) Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 282, 254260.CrossRefGoogle ScholarPubMed
102. Reitz, C, Tang, MX, Manly, J et al. (2008) Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord 25, 232237.CrossRefGoogle Scholar
103. Romas, SN, Tang, MX, Berglund, L et al. (1999) APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53, 517521.CrossRefGoogle Scholar
104. Harris, WS, Mozaffarian, D, Lefevre, M et al. (2009) Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 139, 804S819S.CrossRefGoogle ScholarPubMed
105. Connor, WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 71, 1 Suppl., 171S–1715S.CrossRefGoogle Scholar
106. Carrie, I, Clement, M, de Javel, D et al. (2000) Specific phospholipid fatty acid composition of brain regions in mice. Effects of n-3 polyunsaturated fatty acid deficiency and phospholipid supplementation. J Lipid Res 41, 465472.CrossRefGoogle ScholarPubMed
107. Connor, WE, Neuringer, M & Lin, DS (1990) Dietary effects on brain fatty acid composition: The reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J Lipid Res 31, 237247.CrossRefGoogle ScholarPubMed
108. Gamoh, S, Hashimoto, M, Sugioka, K et al. (1999) Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 93, 237241.CrossRefGoogle ScholarPubMed
109. Suzuki, H, Park, SJ, Tamura, M et al. (1998) Effect of the long-term feeding of dietary lipids on the learning ability, fatty acid composition of brain stem phospholipids and synaptic membrane fluidity in adult mice: A comparison of sardine oil diet with palm oil diet. Mech Ageing Dev 101, 119128.CrossRefGoogle ScholarPubMed
110. Moriguchi, T, Greiner, RS & Salem, N Jr. (2000) Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J Neurochem 75, 25632573.CrossRefGoogle ScholarPubMed
111. Lim, SYSH (2000) Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J Nutr 130, 16291632.CrossRefGoogle ScholarPubMed
112. Lim, SY & Suzuki, H (2000) Effect of dietary docosahexaenoic acid and phosphatidylcholine on maze behavior and fatty acid composition of plasma and brain lipids in mice. Int J Vitam Nutr Res 70, 251259.CrossRefGoogle ScholarPubMed
113. Greiner, RS, Moriguchi, T, Hutton, A et al. (1999) Rats with low levels of brain docosahexaenoic acid show impaired performance in olfactory-based and spatial learning tasks. Lipids 34, Suppl., 239243.CrossRefGoogle ScholarPubMed
114. Minami, M, Kimura, S, Endo, T et al. (1997) Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 58, 11231129.CrossRefGoogle ScholarPubMed
115. Jensen, MM, Skarsfeldt, T & Hoy, CE (1996) Correlation between level of (n-3) polyunsaturated fatty acids in brain phospholipids and learning ability in rats. A multiple generation study. Biochim Biophys Acta 1300, 203209.CrossRefGoogle ScholarPubMed
116. Yamamoto, N, Saitoh, M, Moriuchi, A et al. (1987) Effect of dietary alpha-linolenate/linoleate balance on brain lipid compositions and learning ability of rats. J Lipid Res 28, 144151.CrossRefGoogle ScholarPubMed
117. Gamoh, S, Hashimoto, M, Hossain, S et al. (2001) Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 28, 266270.CrossRefGoogle ScholarPubMed
118. Lim, S & Suzuki, H (2001) Changes in maze behavior of mice occur after sufficient accumulation of docosahexaenoic acid in brain. J Nutr 131, 319324.CrossRefGoogle ScholarPubMed
119. Sugimoto, Y, Taga, C, Nishiga, M et al. (2002) Effect of docosahexaenoic acid-fortified Chlorella vulgaris strain CK22 on the radial maze performance in aged mice. Biol Pharm Bull 25, 10901092.CrossRefGoogle ScholarPubMed
120. Itokazu, N, Ikegaya, Y, Nishikawa, M et al. (2000) Bidirectional actions of docosahexaenoic acid on hippocampal neurotransmissions in vivo . Brain Research 862, 211216.CrossRefGoogle ScholarPubMed
121. McGahon, BM, Martin, DS, Horrobin, DF et al. (1999) Age-related changes in synaptic function: Analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 94, 305314.CrossRefGoogle ScholarPubMed
122. Poling, JS, Vicini, S, Rogawski, MA et al. (1996) Docosahexaenoic acid block of neuronal voltage-gated K+ channels: Subunit selective antagonism by zinc. Neuropharmacology 35, 969982.CrossRefGoogle ScholarPubMed
123. Vreugdenhil, M, Bruehl, C, Voskuyl, RA et al. (1996) Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci USA 93, 1255912563.CrossRefGoogle ScholarPubMed
124. Xiao, Y & Li, X (1999) Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 846, 112121.CrossRefGoogle ScholarPubMed
125. Young, C, Gean, PW, Chiou, LC et al. (2000) Docosahexaenoic acid inhibits synaptic transmission and epileptiform activity in the rat hippocampus. Synapse 37, 9094.3.0.CO;2-Z>CrossRefGoogle ScholarPubMed
126. Chalon, S, Delion-Vancassel, S, Belzung, C et al. (1998) Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 128, 25122519.CrossRefGoogle ScholarPubMed
127. de la Presa Owens, S & Innis, SM (1999) Docosahexaenoic and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotransmitters in frontal cortex caused by a linoleic and alpha-linolenic acid deficient diet in formula-fed piglets. J Nutr 129, 20882093.CrossRefGoogle ScholarPubMed
128. Delion, S, Chalon, S, Guilloteau, D et al. (1996) alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 66, 15821591.CrossRefGoogle ScholarPubMed
129. Innis, SM (2000) The role of dietary n-6 and n-3 fatty acids in the developing brain. Dev Neurosci 22, 474480.CrossRefGoogle ScholarPubMed
130. Ikemoto, A, Nitta, A, Furukawa, S et al. (2000) Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci Lett 285, 99–102.CrossRefGoogle ScholarPubMed
131. Okada, M, Amamoto, T, Tomonaga, M et al. (1996) The chronic administration of docosahexaenoic acid reduces the spatial cognitive deficit following transient forebrain ischemia in rats. Neuroscience 71, 1725.CrossRefGoogle ScholarPubMed
132. He, K, Song, Y, Daviglus, ML et al. (2004) Fish consumption and incidence of stroke: A meta-analysis of cohort studies. Stroke 35, 15381542.CrossRefGoogle ScholarPubMed
133. Barberger-Gateau, P, Letenneur, L, Deschamps, V et al. (2002) Fish, meat, and risk of dementia: Cohort study. Br Med J 325, 932933.CrossRefGoogle ScholarPubMed
134. Huang, TL, Zandi, PP, Tucker, KL et al. (2005) Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 65, 14091414.CrossRefGoogle ScholarPubMed
135. Kalmijn, S, Launer, LJ, Ott, A et al. (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 42, 776782.CrossRefGoogle ScholarPubMed
136. Morris, MC, Evans, DA, Bienias, JL et al. (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60, 940946.CrossRefGoogle ScholarPubMed
137. Schaefer, EJ, Bongard, V, Beiser, AS et al. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch Neurol 63, 15451550.CrossRefGoogle ScholarPubMed
138. Larrieu, S, Letenneur, L, Helmer, C et al. (2004) Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging 8, 150154.Google ScholarPubMed
139. Gillum, RF, Mussolino, ME & Madans, JH (1996) The relationship between fish consumption and stroke incidence. The NHANES I Epidemiologic Follow-up Study (National Health and Nutrition Examination Survey). Arch Intern Med 156, 537542.CrossRefGoogle ScholarPubMed
140. Iso, H, Rexrode, KM, Stampfer, MJ et al. (2001) Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 285, 304312.CrossRefGoogle ScholarPubMed
141. Keli, SO, Feskens, EJ & Kromhout, D (1994) Fish consumption and risk of stroke. The Zutphen Study. Stroke 25, 328332.CrossRefGoogle ScholarPubMed
142. Orencia, AJ, Daviglus, ML, Dyer, AR et al. (1996) Fish consumption and stroke in men. 30-year findings of the Chicago Western Electric Study. Stroke 27, 204209.CrossRefGoogle ScholarPubMed
143. Morris, MC, Evans, DA, Tangney, CC et al. (2005) Fish consumption and cognitive decline with age in a large community study. Arch Neurol 62, 18491853.CrossRefGoogle Scholar
144. Devore, EE, Grodstein, F, van Rooij, FJ et al. (2009) Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 90, 170176.CrossRefGoogle ScholarPubMed
145. Barberger-Gateau, P, Raffaitin, C, Letenneur, L et al. (2007) Dietary patterns and risk of dementia: The Three-City cohort study. Neurology 69, 19211930.CrossRefGoogle ScholarPubMed
146. Belin, RJ, Greenland, P, Martin, L et al. (2011) Fish intake and the risk of incident heart failure: The Women's Health Initiative. Circ Heart Fail 4, 404413.CrossRefGoogle ScholarPubMed
147. Quinn, JF, Raman, R, Thomas, RG et al. (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 304, 19031911.CrossRefGoogle ScholarPubMed
148. van de Rest, O, Geleijnse, JM, Kok, FJ et al. (2008) Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. Neurology 71, 430438.CrossRefGoogle ScholarPubMed
149. van Gelder, BM, Tijhuis, M, Kalmijn, S et al. (2007) Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: The Zutphen Elderly Study. Am J Clin Nutr 85, 11421147.CrossRefGoogle ScholarPubMed
150. Whalley, LJ, Deary, IJ, Starr, JM et al. (2008) n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: An observational follow-up study in late adulthood. Am J Clin Nutr 87, 449454.CrossRefGoogle ScholarPubMed
151. Hunter, D. (1998) Biochemical indicators of dietary intake. In Nutritional Epidemiology , pp. 174243 [Willett, WC]. New York: Oxford University Press.Google Scholar
152. Molloy, AM & Scott, JM (2001) Folates and prevention of disease. Public Health Nutr 4, 601609.CrossRefGoogle ScholarPubMed
153. Quinivan, EP & Gregory, JF (2003) Effect of food fortification on folic acid intakes in the United States. Am J Clin Nutr 77, 221226.CrossRefGoogle Scholar
154. Kalmbach, RD, Choumenkovitch, SF, Troen, AM et al. (2008) Circulating folic acid in plasma: Relation to folic acid fortification. Am J Clin Nutr 88, 763768.CrossRefGoogle ScholarPubMed
155. Herbert, V & Das, KC. (1994) Folic Acid and Vitamin B12. In Modern Nutrition in Health and Disease , 8th ed., p. 402425 [Shils, M, Olson, JA & Shike, M]. Philadelphia: Lea & Febiger.Google Scholar
156. Savage, DG & Lindenbaum, J (1995) Neurological complications of acquired cobalamin deficiency: Clinical aspects. [Review] [114 refs]. Baillieres Clin Haematol 8, 657678.CrossRefGoogle Scholar
157. Carmel, R (1997) Cobalamin, the stomach, and aging. Am J Clin Nutr 66, 750759.CrossRefGoogle ScholarPubMed
158. Pfeiffer, CM, Caudill, SP, Gunter, EW et al. (2005) Biochemical indicators of B vitamin status in the US population after folic acid fortification: Results from the National Health and Nutrition Examination Survey 1999–2000. Am J Clin Nutr 82, 442450.CrossRefGoogle ScholarPubMed
159. Seshadri, S, Beiser, A, Selhub, J et al. (2002) Plasma homocysteine as a risk factor dementia and Alzheimer's disease. N Engl J Med 346, 476483.CrossRefGoogle ScholarPubMed
160. Haan, MN, Miller, JW, Aiello, AE et al. (2007) Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: Results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 85, 511517.CrossRefGoogle Scholar
161. Luchsinger, JA, Tang, MX, Shea, S et al. (2004) Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62, 19721976.CrossRefGoogle ScholarPubMed
162. Ho, PI, Collins, SC, Dhitavat, S et al. (2001) Homocysteine potentiates beta-amyloid neurotoxicity: Role of oxidative stress. J Neurochem 78, 249253.CrossRefGoogle ScholarPubMed
163. Tchantchou, F & Shea, TB (2008) Folate deprivation, the methionine cycle, and Alzheimer's disease. Vitam Horm 79, 8397.CrossRefGoogle ScholarPubMed
164. Mooijaart, SP, Gussekloo, J, Frolich, M et al. (2005) Homocysteine, vitamin B-12, and folic acid and the risk of cognitive decline in old age: The Leiden 85-Plus study. Am J Clin Nutr 82, 866871.CrossRefGoogle ScholarPubMed
165. Tucker, KL, Qiao, N, Scott, T et al. (2005) High homocysteine and low B vitamins predict cognitive decline in aging men: The Veterans Affairs Normative Aging Study. Am J Clin Nutr 82, 627635.CrossRefGoogle Scholar
166. Kado, DM, Karlamangla, AS, Huang, MH et al. (2005) Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 118, 161167.CrossRefGoogle ScholarPubMed
167. Kim, JM, Kim, SW, Shin, IS et al. (2008) Folate, vitamin b(12), and homocysteine as risk factors for cognitive decline in the elderly. Psychiatry Invest 5, 3640.CrossRefGoogle ScholarPubMed
168. Morris, MC, Evans, DA, Bienias, JL et al. (2005) Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol 62, 641645.CrossRefGoogle ScholarPubMed
169. Tangney, CC, Tang, Y, Evans, DA et al. (2009) Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline. Neurology 72, 361367.CrossRefGoogle ScholarPubMed
170. Clarke, R, Birks, J, Nexo, E et al. (2007) Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr 86, 13841391.CrossRefGoogle ScholarPubMed
171. Kang, JH, Irizarry, MC & Grodstein, F (2006) Prospective study of plasma folate, vitamin B12, and cognitive function and decline. Epidemiology 17, 650657.CrossRefGoogle ScholarPubMed
172. Garcia, AA, Haron, Y, Evans, LR et al. (2004) Metabolic markers of cobalamin deficiency and cognitive function in normal older adults. J Am Geriatr Soc 52, 6671.CrossRefGoogle ScholarPubMed
173. Teunissen, CE, Blom, AH, van Boxtel, MP et al. (2003) Homocysteine: A marker for cognitive performance? A longitudinal follow-up study. J Nutr Health Aging 7, 153159.Google ScholarPubMed
174. McCaddon, A, Hudson, P, Abrahamsson, L et al. (2001) Analogues, ageing and aberrant assimilation of vitamin B12 in Alzheimer's disease. Dement Geriatr Cogn Disord 12, 133137.CrossRefGoogle ScholarPubMed
175. Morris, MS, Jacques, PF, Rosenberg, IH et al. (2007) Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 85, 193200.CrossRefGoogle ScholarPubMed
176. Luchsinger, JA, Tang, MX, Miller, J et al. (2007) Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol 64, 8692.CrossRefGoogle ScholarPubMed
177. Ravaglia, G, Forti, P, Maioli, F et al. (2005) Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 82, 636643.CrossRefGoogle ScholarPubMed
178. Corrada, MM, Kawas, CH, Hallfrisch, J et al. (2005) Reduced risk of Alzheimer's disease with high folate intake: The Baltimore Longitudinal Study of Aging. Alzheimers Dement 1, 1118.CrossRefGoogle ScholarPubMed
179. Wang, HX, Wahlin, A, Basun, H et al. (2001) Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 56, 11881194.CrossRefGoogle Scholar
180. Kim, JM, Stewart, R, Kim, SW et al. (2008) Changes in folate, vitamin B12 and homocysteine associated with incident dementia. J Neurol Neurosurg Psychiatry 79, 864868.CrossRefGoogle ScholarPubMed
181. Morris, MC, Evans, DA, Bienias, JL et al. (2004) Dietary niacin and risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry 75, 10931099.CrossRefGoogle ScholarPubMed
182. Nelson, C, Wengreen, HJ, Munger, RG et al. (2009) Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: The cache county memory, health and aging study. J Nutr Health Aging 13, 899905.CrossRefGoogle ScholarPubMed
183. Durga, J, van Boxtel, MP, Schouten, EG et al. (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 369, 208216.CrossRefGoogle Scholar
184. de Jager, CA, Oulhaj, A & Jacoby, R (2011) Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. Int J Geriatr Psychiatry (Epublication ahead of print version).Google ScholarPubMed
185. McMahon, JA, Green, TJ & Skeaff, CM (2006) A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354, 27642772.CrossRefGoogle ScholarPubMed
186. Kang, JH, Cook, N, Manson, J et al. (2008) A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr 88, 16021610.CrossRefGoogle ScholarPubMed
187. Smith, AD, Smith, SM, de Jager, CA et al. (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS ONE 5, e12244.CrossRefGoogle Scholar
188. Chodos, RB & Ross, JF (1951) The effects of combined folic acid and liver extract therapy. Blood 6, 12131233.CrossRefGoogle ScholarPubMed
189. Scarmeas, N, Stern, Y & Mayeux, R (2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66, 216225.Google ScholarPubMed
190. Feart, C, Samieri, C, Rondeau, V et al. (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302, 638648.CrossRefGoogle ScholarPubMed
191. Tangney, CC, Kwasny, MJ, Li, H et al. (2011) Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr 93, 601607.CrossRefGoogle Scholar
192. Scarmeas, N, Stern, Y, Mayeux, R et al. (2006) Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol 63, 17091717.CrossRefGoogle ScholarPubMed
193. Sundelof, J, Kilander, L, Helmersson, J et al. (2009) Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: A prospective population-based study. J Alzheimers Dis 18, 7178.CrossRefGoogle ScholarPubMed
194. Wengreen, HJ, Munger, RG, Corcoran, CD et al. (2007) Antioxidant intake and cognitive function of elderly men and women: The Cache County Study. J Nutr Health Aging 11, 230237.Google ScholarPubMed
195. Morris, MC, Evans, DA, Tangney, CC et al. (2005) Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 81, 508514.CrossRefGoogle ScholarPubMed
196. Commenges, D, Scotet, V, Renaud, S et al. (2000) Intake of flavonoids and risk of dementia. Eur J Epidemiol 16, 357363.CrossRefGoogle ScholarPubMed
197. Berr, C, Balansard, B, Arnaud, J et al. (2000) Cognitive decline is associated with systemic oxidative stress: The EVA study. Etude du Vieillissement Arteriel. J Am Geriatr Soc 48, 12851291.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Prospective studies of dietary antioxidant nutrients and dementia outcomes*